Terms: = Thyroid cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2 AND Treatment
90 results:
1. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
2. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
3. Establishment and Characterization of Amitrole-Induced Mouse thyroid Adenomatous Nodule-Derived Cell Lines.
Shirai YT; Hoshi N; Ward JM; Liu H; Cachau RE; Lee MP; Kimura S
Thyroid; 2024 Apr; 34(4):496-509. PubMed ID: 38149583
[No Abstract] [Full Text] [Related]
4. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic thyroid cancer.
Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
[TBL] [Abstract] [Full Text] [Related]
5. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
Toda S; Iwasaki H; Okubo Y; Hayashi H; Kadoya M; Takahashi H; Yokose T; Hiroshima Y; Masudo K
Endocr J; 2024 Jan; 71(1):31-37. PubMed ID: 38044137
[TBL] [Abstract] [Full Text] [Related]
6. Risk-stratified Distant Metastatic thyroid cancer with Clinicopathological Factors and BRAF/tert Promoter Mutations.
Cheng X; Zhou Y; Xu S; Yu H; Wu J; Bao J; Zhang L
Exp Clin Endocrinol Diabetes; 2023 Nov; 131(11):577-582. PubMed ID: 37922948
[TBL] [Abstract] [Full Text] [Related]
7. Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.
Cleere EF; Prunty S; O'Neill JP
Surgeon; 2024 Feb; 22(1):e48-e53. PubMed ID: 37866980
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary thyroid cancer.
Schumm MA; Shu ML; Hughes EG; Nikiforov YE; Nikiforova MN; Wald AI; Lechner MG; Tseng CH; Sajed DP; Wu JX; Yeh MW; Livhits MJ
JAMA Otolaryngol Head Neck Surg; 2023 Aug; 149(8):735-742. PubMed ID: 37382944
[TBL] [Abstract] [Full Text] [Related]
9. BRAF-AXL-PD-L1 Signaling Axis as a Possible Biological Marker for RAI treatment in the thyroid cancer ATA Intermediate Risk Category.
Pizzimenti C; Fiorentino V; Ieni A; Rossi ED; Germanà E; Giovanella L; Lentini M; Alessi Y; Tuccari G; Campennì A; Martini M; Fadda G
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373171
[TBL] [Abstract] [Full Text] [Related]
10. Neoadjuvant therapy with anlotinib in a locally advanced and pulmonary metastasis PTC patient harboring tert promoter and BRAF
Su YJ; Cheng SH; Qian J; Zhang M; Liu W; Zhan XX; Wang ZQ; Liu HD; Zhong XW; Cheng RC
Arch Endocrinol Metab; 2023 Jun; 67(6):e000659. PubMed ID: 37364156
[TBL] [Abstract] [Full Text] [Related]
11. Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up.
Nilsson JN; Siikanen J; Condello V; Jatta K; Saini R; Hedman C; Ihre Lundgren C; Juhlin CC
Eur Thyroid J; 2023 Jul; 12(4):. PubMed ID: 37352166
[TBL] [Abstract] [Full Text] [Related]
12. Predictive factors for nodal recurrence in differentiated thyroid cancers.
Kaur J; Nadarajan A; Janardhan D; George NA; Thomas S; Varghese BT; Krishna J
Cancer Treat Res Commun; 2023; 36():100728. PubMed ID: 37336036
[TBL] [Abstract] [Full Text] [Related]
13. Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle.
Turkmen E; Sogutlu F; Erdogan M; Biray Avci C
Med Oncol; 2023 Jun; 40(7):196. PubMed ID: 37284891
[TBL] [Abstract] [Full Text] [Related]
14. Genetic Considerations in the Tumorigenesis, Diagnosis, and treatment of Differentiated thyroid cancer: Current State of the Science.
Richmond BK; Gallimore J
Am Surg; 2023 Nov; 89(11):4853-4859. PubMed ID: 37253623
[TBL] [Abstract] [Full Text] [Related]
15. Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis.
Staubitz JI; Müller C; Heymans A; Merten C; Roos B; Poplawski A; Ludt A; Strobl S; Springer E; Schad A; Roth W; Musholt TJ; Hartmann N
BJS Open; 2023 May; 7(3):. PubMed ID: 37146205
[TBL] [Abstract] [Full Text] [Related]
16. BRAF
Choi JH; Yu HW; Lee JK; Kim W; Choi JY; Na HY; Park SY; Ahn CH; Moon JH; Choi SI; Lee HY; Lee WW; Cha W; Jeong WJ
World J Surg Oncol; 2023 Feb; 21(1):49. PubMed ID: 36804879
[TBL] [Abstract] [Full Text] [Related]
17. Gonadal Function in Male Patients With Metastatic Renal Cell cancer Treated With Sunitinib.
Volta AD; Delbarba A; Valcamonico F; Cappelli C; Caramella I; Bergamini M; Ferlin A; Berruti A
In Vivo; 2023; 37(1):410-416. PubMed ID: 36593059
[TBL] [Abstract] [Full Text] [Related]
18. Primary thyroid Mucoepidermoid Carcinoma (MEC) Is Clinically, Prognostically, and Molecularly Different from Sclerosing MEC with Eosinophilia: A Multicenter and Integrated Study.
Le HT; Nguyen TPX; Hirokawa M; Katoh R; Mitsutake N; Matsuse M; Sako A; Kondo T; Vasan N; Kim YM; Liu Y; Hassell L; Kakudo K; Vuong HG
Endocr Pathol; 2023 Mar; 34(1):100-111. PubMed ID: 36394696
[TBL] [Abstract] [Full Text] [Related]
19. thyroid carcinoma-featured telomerase activation and telomere maintenance: Biology and translational/clinical significance.
Yuan X; Yuan H; Zhang N; Liu T; Xu D
Clin Transl Med; 2022 Nov; 12(11):e1111. PubMed ID: 36394204
[TBL] [Abstract] [Full Text] [Related]
20. AST-487 Inhibits RET Kinase Driven tert Expression in Bladder cancer.
Agarwal N; Zhou Q; Arya D; Rinaldetti S; Duex J; LaBarbera DV; Theodorescu D
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142729
[TBL] [Abstract] [Full Text] [Related]
[Next]
